Global Adult Vaccines Market to be USD 20 Billion by 2022
For more Information: http://www.renub.com/adult-vaccines-market-to-be-usd-20-billion-by-2022-35-nd.php Adult Vaccines consists of biological products used to enhance the immune response of a body to protect against diseases like Influenza and Pneumococcal vaccines, Cervical Cancer (HPV), Hepatitis and Travel vaccines, Zoster, Meningococcal, Tdap and MMRV. The adult vaccines market is driven by many factors as the occurrence of diseases, increasing government and non-government accounts for the development of vaccines as well as investments by companies. High potential growth and rising markets and development of therapeutic and adjuvant vaccines have opened opportunities for the adult vaccines market market. However, the growth of global vaccines markets is hampering by huge capital investments and stringent regulations.
For more Information: http://www.renub.com/adult-vaccines-market-to-be-usd-20-billion-by-2022-35-nd.php
Adult Vaccines consists of biological products used to enhance the immune response of a body to protect against diseases like Influenza and Pneumococcal vaccines, Cervical Cancer (HPV), Hepatitis and Travel vaccines, Zoster, Meningococcal, Tdap and MMRV. The adult vaccines market is driven by many factors as the occurrence of diseases, increasing government and non-government accounts for the development of vaccines as well as investments by companies. High potential growth and rising markets and development of therapeutic and adjuvant vaccines have opened opportunities for the adult vaccines market market. However, the growth of global vaccines markets is hampering by huge capital investments and stringent regulations.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Adult</strong> <strong>Vaccines</strong> <strong>Market</strong>, Company <strong>Adult</strong> <strong>Vaccines</strong> Sales, Country <strong>Adult</strong> <strong>Vaccines</strong> - Worldwide<br />
Analysis<br />
<strong>Global</strong> <strong>Adult</strong> <strong>Vaccines</strong> <strong>Market</strong> and Sales<br />
Analyst View:<br />
<strong>Adult</strong> <strong>Vaccines</strong> <strong>Market</strong> is projected <strong>to</strong> <strong>be</strong> US$ <strong>20</strong> <strong>Billion</strong> <strong>by</strong> the year <strong>20</strong>22. <strong>Vaccines</strong> can<br />
prevent the death rate from diseases like Pneumococcal and Influenza related complications in<br />
the adults.<br />
For More Information:<br />
http://www.renub.com/adult-vaccines-market-<strong>to</strong>-<strong>be</strong>-usd-<strong>20</strong>-billion-<strong>by</strong>-<strong>20</strong>22-35-nd.php<br />
Download full Report:<br />
http://www.renub.com/adult-vaccines-market-company-adult-vaccines-sales-country-adultvaccines-worldwide-analysis-19-p.php<br />
Get 10% Free Cus<strong>to</strong>mization in this Report<br />
<strong>Adult</strong> <strong>Vaccines</strong> <strong>Market</strong> is projected <strong>to</strong> <strong>be</strong> US$ <strong>20</strong> <strong>Billion</strong> <strong>by</strong> the year <strong>20</strong>22. <strong>Vaccines</strong> can prevent the<br />
death rate from diseases like Pneumococcal and Influenza related complications in the<br />
adults. National Immunization Programme has <strong>be</strong>en introduced <strong>by</strong> almost all the countries of<br />
the world in their vaccination schedule <strong>to</strong> overcome the epidemics caused <strong>by</strong> Vaccine<br />
preventable diseases. <strong>Global</strong> Immunization Vision and Strategy (GIVS), WHO’s <strong>Global</strong> Vaccine<br />
Action Plan, <strong>to</strong> minimize the occurrences of vaccine preventable diseases, the GAVI associations are<br />
putting their <strong>be</strong>st efforts.<br />
<strong>Adult</strong> <strong>Vaccines</strong> consists of biological products used <strong>to</strong> enhance the immune response of a body <strong>to</strong><br />
protect against diseases like Influenza and Pneumococcal vaccines, Cervical Cancer (HPV), Hepatitis<br />
and Travel vaccines, Zoster, Meningococcal, Tdap and MMRV. The adult vaccines market is driven <strong>by</strong><br />
many fac<strong>to</strong>rs as the occurrence of diseases, increasing government and non-government accounts for<br />
the development of vaccines as well as investments <strong>by</strong> companies. High potential growth and rising<br />
markets and development of therapeutic and adjuvant vaccines have opened opportunities for the<br />
adult vaccines market market. However, the growth of global vaccines markets is hampering <strong>by</strong> huge<br />
capital investments and stringent regulations.<br />
© Renub Research LLP Page 1 of 3
<strong>Adult</strong> <strong>Vaccines</strong> <strong>Market</strong>, Company <strong>Adult</strong> <strong>Vaccines</strong> Sales, Country <strong>Adult</strong> <strong>Vaccines</strong> - Worldwide<br />
Analysis<br />
Influenza <strong>Vaccines</strong> Dominates the <strong>Adult</strong> <strong>Vaccines</strong> <strong>Market</strong><br />
Influenza vaccine dominates the adult vaccines market in the year <strong>20</strong>17. <strong>Global</strong>ly almost all the<br />
countries, recommends the influenza vaccine <strong>to</strong> <strong>be</strong> taken annually due <strong>to</strong> increasing awareness and<br />
efficiency of the vaccine in preventing diseases. Influenza vaccine holds the maximum share in<strong>to</strong> the<br />
adult vaccines market. However, it will lose its control <strong>to</strong> the Pneumococcal vaccine in the coming<br />
years. Other than Influenza and Pneumococcal vaccines, Cervical Cancer (HPV), Hepatitis and Travel<br />
vaccines, Zoster, Meningococcal, Tdap and MMRV also have substantial market share in <strong>Adult</strong><br />
<strong>Vaccines</strong> <strong>Market</strong> until the year <strong>20</strong>22.<br />
The Report Studies the <strong>Adult</strong> <strong>Vaccines</strong> <strong>Market</strong> on the basis of:<br />
<strong>Vaccines</strong> <strong>Market</strong> (<strong>20</strong>11 – <strong>20</strong>22)<br />
1. Influenza <strong>Vaccines</strong><br />
2. Cervical Cancer <strong>Vaccines</strong><br />
3. Zoster (Shingles) <strong>Vaccines</strong><br />
4. MMRV (Measles, Mumps, Ru<strong>be</strong>lla and Varicella) <strong>Vaccines</strong><br />
5. Pneumonia <strong>Vaccines</strong><br />
6. Meningitis <strong>Vaccines</strong><br />
7. Hepatitis <strong>Vaccines</strong><br />
8. DTap (Diphtheria, Tetanus, Pertussis) <strong>Vaccines</strong><br />
9. Travel & Miscellaneous Vaccine<br />
© Renub Research LLP Page 2 of 3
<strong>Adult</strong> <strong>Vaccines</strong> <strong>Market</strong>, Company <strong>Adult</strong> <strong>Vaccines</strong> Sales, Country <strong>Adult</strong> <strong>Vaccines</strong> - Worldwide<br />
Analysis<br />
Key Players (<strong>20</strong>11 – <strong>20</strong>22)<br />
1. GlaxoSmithKline, plc<br />
2. Merck & Co.<br />
3. Sanofi Pasteur’s<br />
4. Pfizer, Inc.’s<br />
<strong>Vaccines</strong> Report:<br />
http://www.renub.com/vaccines-12-c.php<br />
Renub Research - North America<br />
Rajat Gupta<br />
225 Kristie Ln, Roswell<br />
Georgia 30076, United States<br />
Renub Research - Asia<br />
Ankit Mishra<br />
C – 86, Sec<strong>to</strong>r – 10<br />
Noida <strong>20</strong>1301, India<br />
Tel: +1-678-302-0700<br />
Email: info@renub.com<br />
www.renub.com<br />
Tel: +91-1<strong>20</strong>-421-9822<br />
Email: info@renub.com<br />
www.renub.com<br />
© Renub Research LLP Page 3 of 3
Change language